An oral suspension form of Radicava (edaravone), an approved treatment of amyotrophic lateral sclerosis (ALS), was favored for patient reimbursement in Canada by a branch of the Canadian Agency for Drugs and Technologies in Health (CADTH). The opinion issued by the CADTH Canadian Drug Expert Committee recommended that Radicava Oral…
The Muscular Dystrophy Association (MDA) has invested $600,000 in PathMaker Neurosystems to help bring a potential noninvasive neuromodulator for amyotrophic lateral sclerosis (ALS) into an initial clinical trial. Funding through the MDA Venture Philanthropy (MVP) program will support an early feasibility study in a small…
Inflamed Pharma, part of the incubator and accelerator company Xlife Sciences, is partnering with researchers at the University Medical Center Gottingen in Germany to develop its investigational therapy ProcCluster for the treatment of amyotrophic lateral sclerosis (ALS). The collaboration, led by Jan C. Koch, MD, a principal investigator…
Scientists have developed a new method that allows them to grow mature nerve cells from stem cells — a technique that could be applied to study diseases like amyotrophic lateral sclerosis (ALS). “For the first time, we have been able to see adult-onset neurological protein aggregation in the stem…
Synchron‘s Stentrode, an implantable brain-computer interface designed to allow people with amyotrophic lateral sclerosis (ALS) and other paralyzing conditions to control a computer using their thoughts, showed a positive safety profile in a small clinical trial. The four people in the Australian study had ALS and severe…
A new formulation of MediciNova’s investigational amyotrophic lateral sclerosis treatment ibudilast (MN-166) given via an intravenous (into the vein) infusion was found to be safe and well tolerated in healthy volunteers. That’s according to data from a recently completed Phase 1 clinical trial that tested the safety and…
Biological samples from amyotrophic lateral sclerosis (ALS) patients who took part in the Phase 3 clinical trial of NurOwn, a cell-based therapy, are being donated by BrainStorm Cell Therapeutics to a repository for use by the research community. The samples include blood and spinal fluid (cerebrospinal fluid or CSF)…
ANX005, an experimental medication being developed by Annexon Biosciences for neurodegenerative and autoimmune diseases, resulted in a slowing of disease progression in adults with amyotrophic lateral sclerosis (ALS). That’s according to preliminary data from eight patients taking part in a Phase 2a clinical study (NCT04569435), whose main…
The bacterial strain Lacticaseibacillus rhamnosus HA-114 prevents neurodegeneration and preserves motor function in worm models of amyotrophic lateral sclerosis (ALS), a new study reports. This protective effect was linked to the fat molecules, called fatty acids, found in this strain, which helped restore fat metabolism in the mitochondria —…
A Phase 1 clinical trial has begun dosing adult healthy volunteers to investigate QurAlis Corporation‘s QRL-101, an oral treatment candidate for amyotrophic lateral sclerosis (ALS), the company announced. The first-in-human Phase 1 trial (NCT05667779) aims to assess the safety, tolerability, and pharmacokinetics — the movement of a…
Get regular updates to your inbox.
